This clinical trial is focused on studying a condition known as Relapsed or Refractory Multiple Myeloma, which is a type of blood cancer that affects plasma cells in the bone marrow. The study aims to compare the effectiveness of different treatment combinations for this condition. One group of participants will receive a combination of Teclistamab and Daratumumab (referred to as Tec-Dara), while another group will receive a combination of Daratumumab, Pomalidomide, and Dexamethasone (referred to as DPd). A third group will receive Daratumumab, Bortezomib, and Dexamethasone (referred to as DVd). Daratumumab and Teclistamab are given as injections under the skin, while Pomalidomide, Dexamethasone, and Bortezomib are taken orally in capsule or tablet form.
The purpose of the study is to compare the effectiveness of these treatment combinations in managing the disease. Participants will be randomly assigned to one of the treatment groups and will receive their respective treatments over a specified period. The study will monitor the participants’ health and response to the treatments to gather data on how well each combination works. This will help in understanding which treatment option might be more beneficial for patients with this type of multiple myeloma.
Throughout the study, participants will undergo regular health check-ups and assessments to ensure their safety and to track the progress of their condition. The study is designed to provide valuable insights into the treatment of Relapsed or Refractory Multiple Myeloma and aims to improve the options available for managing this challenging condition.
Belgium 
Denmark 
France 
Germany 
Greece 
Italy 
Poland 
Spain 
Sweden 
The Netherlands 